SBIR Phase 2: Development of GISMO Compounds for the Treatment of Alzheimer's Disease

Grants and Contracts Details

StatusFinished
Effective start/end date12/11/17 → 5/31/20

Funding

  • Gismo Therapeutics Incorporated: $256,440.00